Nuveen, LLC Madrigal Pharmaceuticals, Inc. Transaction History
Nuveen, LLC
- $348 Billion
- Q2 2025
A detailed history of Nuveen, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Nuveen, LLC holds 41,533 shares of MDGL stock, worth $18.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,533
Previous 49,922
16.8%
Holding current value
$18.7 Million
Previous $16.5 Million
23.99%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding MDGL
# of Institutions
356Shares Held
23.2MCall Options Held
738KPut Options Held
473K-
Janus Henderson Group PLC London, X02.19MShares$985 Million0.34% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.09MShares$940 Million32.86% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$896 Million9.27% of portfolio
-
Baker Bros. Advisors LP New York, NY1.98MShares$888 Million6.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.88MShares$844 Million0.01% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $7.69B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...